These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23868091)

  • 21. Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years.
    Liang PS; Wheat CL; Abhat A; Brenner AT; Fagerlin A; Hayward RA; Thomas JP; Vijan S; Inadomi JM
    Am J Gastroenterol; 2016 Jan; 111(1):105-14. PubMed ID: 26526080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal occult blood testing: a false sense of security?
    Schnell T; Aranha GV; Sontag SJ; Tode R; Reid S; Chejfec G; Karpf J; Levine G
    Surgery; 1994 Oct; 116(4):798-802; discussion 802-3. PubMed ID: 7940181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of a randomized controlled trial to assess the comparative effectiveness of a multifaceted intervention to improve adherence to colorectal cancer screening among patients cared for in a community health center.
    Baker DW; Brown T; Buchanan DR; Weil J; Cameron KA; Ranalli L; Ferreira MR; Stephens Q; Balsley K; Goldman SN; Wolf MS
    BMC Health Serv Res; 2013 Apr; 13():153. PubMed ID: 23627550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study.
    Wei SC; Tsao PN; Wang YT; Lin BR; Wu DC; Tsai WS; Chen JS; Wong JM
    Cancer Med; 2019 Jul; 8(7):3583-3591. PubMed ID: 31063258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physician-office vs home uptake of colorectal cancer screening using FOBT/FIT among screening-eligible US adults.
    Chido-Amajuoyi OG; Sharma A; Talluri R; Tami-Maury I; Shete S
    Cancer Med; 2019 Dec; 8(17):7408-7418. PubMed ID: 31637870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.
    Green BB; Anderson ML; Chubak J; Fuller S; Meenan RT; Vernon SW
    Cancer; 2016 Jan; 122(2):312-21. PubMed ID: 26488332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use and abuse of fecal occult blood tests: a community hospital experience.
    Soin S; Akanbi O; Ahmed A; Kim Y; Pandit S; Wroblewski I; Saleem N
    BMC Gastroenterol; 2019 Sep; 19(1):161. PubMed ID: 31481027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of fecal occult blood testing in hospitalized patients: results of an audit.
    Ip S; Sokoro AA; Kaita L; Ruiz C; McIntyre E; Singh H
    Can J Gastroenterol Hepatol; 2014 Oct; 28(9):489-94. PubMed ID: 25314355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. False-Positive Results in a Population-Based Colorectal Screening Program: Cumulative Risk from 2000 to 2017 with Biennial Screening.
    Ibáñez-Sanz G; Garcia M; Milà N; Hubbard RA; Vidal C; Binefa G; Benito L; Moreno V;
    Cancer Epidemiol Biomarkers Prev; 2019 Nov; 28(11):1909-1916. PubMed ID: 31488415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort.
    Bjerrum A; Lindebjerg J; Andersen O; Fischer A; Lynge E
    Int J Cancer; 2020 Aug; 147(4):940-947. PubMed ID: 31894860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of self-checked fecal occult blood testing for colorectal cancer in Thai patients.
    Lohsiriwat V
    Asian Pac J Cancer Prev; 2014; 15(18):7981-4. PubMed ID: 25292099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term risk of colorectal cancer after negative colonoscopy in a Danish gFOBT screening cohort.
    Bjerrum A; Andersen O; Fischer A; Lindebjerg J; Lynge E
    Int J Cancer; 2017 Aug; 141(3):503-511. PubMed ID: 28463410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Early detection of bowel cancer in occupational surveillance examinations: switching from a guaiak-based to an immunochemical fecal occult blood test].
    Webendörfer S; Riemann JF
    Dtsch Med Wochenschr; 2014 Jan; 139(3):79-83. PubMed ID: 24089288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.